Text and Data Mining valid from 2019-01-26
Received: 15 October 2018
Accepted: 17 January 2019
First Online: 26 January 2019
Compliance with ethical standards
: M.W. was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (=translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire, and LEO Pharma. In addition, the FORTA classification was developed by M.W.F.P. and J.K. declare no conflicts of interest.